CSL appoints Deborah Waterhouse as CEO & Managing Director
CSL Limited appointed Deborah Waterhouse as CEO & Managing Director effective 1 February 2027, following an extensive global search. Waterhouse has led ViiV Healthcare, GSK's majority-owned HIV joint venture with £7.7 billion in FY25 sales, since 2017, and previously ran GSK's US vaccines and primary care businesses. She will remain UK-based while spending significant time in Australia and the US. Gordon Naylor continues as Interim CEO until the transition date, then returns to the Board as a non-executive director.
Key figures
- Rsu buyout
- £7.71m
- Start date
- 1 February 2027
- Base salary
- £1,500,000 per annum
- Psu extra award
- £1.65m
- Viiv sales gsk fy25
- £7.7 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.